Suppr超能文献

肝细胞癌患者肿瘤浸润性CD8 + T细胞的临床病理特征及预后意义:一项荟萃分析。

Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma: A meta-analysis.

作者信息

Xu Xuezhong, Tan Yulin, Qian Yan, Xue Wenbo, Wang Yibo, Du Jianguo, Jin Lei, Ding Wei

机构信息

Department of General Surgery, Wujin Hospital Affiliated to Jiangsu University, Changzhou, Jiangsu Province.

Department of Respiration, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, China.

出版信息

Medicine (Baltimore). 2019 Jan;98(2):e13923. doi: 10.1097/MD.0000000000013923.

Abstract

BACKGROUND

In patients with hepatocellular carcinoma (HCC), the clinicopathologic and prognostic roles of tumor-infiltrating CD8+ T cells for survival are still controversial. A meta-analysis was performed to resolve this issue.

METHODS

We identified studies from PubMed, Embase, and the Cochrane Library to evaluate the clinicopathologic and prognostic value of tumor-infiltrating CD8+ T cells in patients with HCC. A meta-analysis was conducted to estimate clinicopathologic characteristics, overall survival (OS), and disease-free survival. The hazard ratio (HR) and 95% confidence interval (CI) were calculated employing fixed-effect or random-effect models depending on the heterogeneity of the included trials.

RESULTS

A total of 3509 patients from 21 observational studies were enrolled. The meta-analysis revealed that high levels of intratumoral CD8+ tumor-infiltrating lymphocytes (TILs) were associated with better OS (OS; HR = 0.676, P = .001) and disease-free survival (disease-free survival [DFS]; HR = 0.712, P = .002). The pooled analysis also demonstrated high density of infiltration of CD8+ TILs in margin of tumor (MT) was statistically significant associated with better OS (HR = 0.577; P <.001). Moreover, the patients with low CD8+ TILs infiltration had negative HBSAg (OR = 1.67, P = .02), large tumor size (OR = 1.74, P <.01), and later TNM stage (OR = 1.70, P <.01).

CONCLUSIONS

Our findings suggested that low levels of CD8+ TILs predict large tumor size, later TNM stage and might be a promising prognostic factor of HCC especially for Asian patients. High-quality randomized controlled trials are needed to determine if CD8+ TILs could serve as targets for immunotherapy in hepatocellular carcinoma.

摘要

背景

在肝细胞癌(HCC)患者中,肿瘤浸润性CD8 + T细胞在生存方面的临床病理及预后作用仍存在争议。进行了一项荟萃分析以解决此问题。

方法

我们从PubMed、Embase和Cochrane图书馆中检索研究,以评估肿瘤浸润性CD8 + T细胞在HCC患者中的临床病理及预后价值。进行荟萃分析以估计临床病理特征、总生存期(OS)和无病生存期。根据纳入试验的异质性,采用固定效应或随机效应模型计算风险比(HR)和95%置信区间(CI)。

结果

共纳入了来自21项观察性研究的3509例患者。荟萃分析显示,肿瘤内CD8 +肿瘤浸润淋巴细胞(TILs)水平高与更好的总生存期(OS;HR = 0.676,P = 0.001)和无病生存期(无病生存期[DFS];HR = 0.712,P = 0.002)相关。汇总分析还表明,肿瘤边缘(MT)处CD8 + TILs的高密度浸润与更好的总生存期具有统计学显著相关性(HR = 0.577;P < 0.001)。此外,CD8 + TILs浸润低的患者乙肝表面抗原阴性(OR = 1.67,P = 0.02)、肿瘤体积大(OR = 1.74,P < 0.01)且TNM分期较晚(OR = 1.70,P < 0.01)。

结论

我们的研究结果表明,CD8 + TILs水平低预示着肿瘤体积大、TNM分期较晚,可能是HCC尤其是亚洲患者的一个有前景的预后因素。需要高质量的随机对照试验来确定CD8 + TILs是否可作为肝细胞癌免疫治疗的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61fb/6336640/945f868dfca4/medi-98-e13923-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验